NRX Pharmaceuticals Inc.

WILMINGTON, Del. , June 16, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced a strategic investor relations partnership with astr partners, a boutique investor relations and capital advisory firm focused on the life sciences sector.» Mehr auf prnewswire.com

WILMINGTON, Del. , June 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced participation in the H.C.» Mehr auf prnewswire.com

Squarepoint Ops LLC purchased a new position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 25,299 shares of the company’s stock, valued at approximately $56,000. Squarepoint Ops LLC owned approximately 0.16% of NRx Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Other institutional investors and hedge funds have also made changes to their positions in the company. Sassicaia Capital Advisers LLC acquired a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at $33,000. Millennium Management LLC purchased a new stake in shares of NRx Pharmaceuticals during the fourth quarter worth $61,000. Anson Funds Management LP raised its holdings in NRx Pharmaceuticals by 30.3% during the fourth quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock valued at $408,000 after buying an additional 43,135 shares in the last quarter. Finally, AdvisorShares Investments LLC raised its holdings in NRx Pharmaceuticals by 138.5% during the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock valued at $683,000 after buying an additional 180,229 shares in the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds. Analysts Set New Price Targets A number of brokerages have recently commented on NRXP. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Ascendiant Capital Markets boosted their price target on NRx Pharmaceuticals from $45.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. D. Boral Capital reaffirmed a “buy” rating and issued a $31.00 target price on shares of NRx Pharmaceuticals in a research report on Friday, June 6th. BTIG Research assumed coverage on NRx Pharmaceuticals in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $18.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $28.50. Get Our Latest Stock Analysis on NRx Pharmaceuticals NRx Pharmaceuticals Trading Down 0.5% NRx Pharmaceuticals stock opened at $3.65 on Wednesday. NRx Pharmaceuticals, Inc. has a 1-year low of $1.10 and a 1-year high of $6.01. The firm has a market capitalization of $63.10 million, a price-to-earnings ratio of -1.71 and a beta of 1.54. The firm has a 50 day simple moving average of $2.28 and a 200 day simple moving average of $2.36. NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.06. The company had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $1.14 million. On average, equities research analysts forecast that NRx Pharmaceuticals, Inc. will post -1.75 EPS for the current year. About NRx Pharmaceuticals (Free Report) NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.» Mehr auf defenseworld.net